Biomarkers for trials of neuroprotection in Parkinson's disease.
Identifieur interne : 000A86 ( Main/Exploration ); précédent : 000A85; suivant : 000A87Biomarkers for trials of neuroprotection in Parkinson's disease.
Auteurs : Pankaj A. Agarwal [Canada] ; A Jon StoesslSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2013.
English descriptors
- KwdEn :
- Animals, Biological Markers (metabolism), Brain (metabolism), Brain (pathology), Disease Progression, Dopamine (diagnostic use), Dopamine (metabolism), Essential Tremor (diagnosis), Humans, Neuroimaging, Neuroprotective Agents (therapeutic use), Parkinson Disease (diagnosis), Parkinson Disease (drug therapy), Parkinson Disease (metabolism).
- MESH :
- chemical , diagnostic use : Dopamine.
- chemical , metabolism : Biological Markers, Dopamine.
- diagnosis : Essential Tremor, Parkinson Disease.
- drug therapy : Parkinson Disease.
- metabolism : Brain, Parkinson Disease.
- pathology : Brain.
- chemical , therapeutic use : Neuroprotective Agents.
- Animals, Disease Progression, Humans, Neuroimaging.
Abstract
With increased understanding of disease pathogenesis and the foreseeable reality of disease-modifying therapies, there is a growing need to find biomarkers that will allow early (preferably preclinical) detection of disease and that will provide an independent readout of disease progression. In this article, we review a variety of markers, with a focus on functional imaging techniques, which while imperfect, currently provide the best approach to this problem. We consider the limitations of functional imaging of the dopamine system in assessing the progression of Parkinson's Disease (PD) as well as the potential use of structural imaging and emerging progress in other biochemical and molecular markers. While there is no single biomarker that will satisfy all requirements, some combination is likely to be of great use in identifying those subjects most likely to benefit from neuroprotective therapies, as well as in monitoring the effects of these interventions.
DOI: 10.1002/mds.25065
PubMed: 22927101
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000C62
- to stream PubMed, to step Curation: 000C62
- to stream PubMed, to step Checkpoint: 000A97
- to stream Ncbi, to step Merge: 003784
- to stream Ncbi, to step Curation: 003784
- to stream Ncbi, to step Checkpoint: 003784
- to stream Main, to step Merge: 000A86
- to stream Main, to step Curation: 000A86
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Biomarkers for trials of neuroprotection in Parkinson's disease.</title>
<author><name sortKey="Agarwal, Pankaj A" sort="Agarwal, Pankaj A" uniqKey="Agarwal P" first="Pankaj A" last="Agarwal">Pankaj A. Agarwal</name>
<affiliation wicri:level="1"><nlm:affiliation>Pacific Parkinson's Research Centre, University of British Columbia, Vancouver, British Columbia, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Pacific Parkinson's Research Centre, University of British Columbia, Vancouver, British Columbia</wicri:regionArea>
<wicri:noRegion>British Columbia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A Jon" last="Stoessl">A Jon Stoessl</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2013">2013</date>
<idno type="doi">10.1002/mds.25065</idno>
<idno type="RBID">pubmed:22927101</idno>
<idno type="pmid">22927101</idno>
<idno type="wicri:Area/PubMed/Corpus">000C62</idno>
<idno type="wicri:Area/PubMed/Curation">000C62</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000A97</idno>
<idno type="wicri:Area/Ncbi/Merge">003784</idno>
<idno type="wicri:Area/Ncbi/Curation">003784</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003784</idno>
<idno type="wicri:Area/Main/Merge">000A86</idno>
<idno type="wicri:Area/Main/Curation">000A86</idno>
<idno type="wicri:Area/Main/Exploration">000A86</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Biomarkers for trials of neuroprotection in Parkinson's disease.</title>
<author><name sortKey="Agarwal, Pankaj A" sort="Agarwal, Pankaj A" uniqKey="Agarwal P" first="Pankaj A" last="Agarwal">Pankaj A. Agarwal</name>
<affiliation wicri:level="1"><nlm:affiliation>Pacific Parkinson's Research Centre, University of British Columbia, Vancouver, British Columbia, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Pacific Parkinson's Research Centre, University of British Columbia, Vancouver, British Columbia</wicri:regionArea>
<wicri:noRegion>British Columbia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A Jon" last="Stoessl">A Jon Stoessl</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2013" type="published">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Biological Markers (metabolism)</term>
<term>Brain (metabolism)</term>
<term>Brain (pathology)</term>
<term>Disease Progression</term>
<term>Dopamine (diagnostic use)</term>
<term>Dopamine (metabolism)</term>
<term>Essential Tremor (diagnosis)</term>
<term>Humans</term>
<term>Neuroimaging</term>
<term>Neuroprotective Agents (therapeutic use)</term>
<term>Parkinson Disease (diagnosis)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (metabolism)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Dopamine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Biological Markers</term>
<term>Dopamine</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Essential Tremor</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Brain</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Brain</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Neuroprotective Agents</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Disease Progression</term>
<term>Humans</term>
<term>Neuroimaging</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">With increased understanding of disease pathogenesis and the foreseeable reality of disease-modifying therapies, there is a growing need to find biomarkers that will allow early (preferably preclinical) detection of disease and that will provide an independent readout of disease progression. In this article, we review a variety of markers, with a focus on functional imaging techniques, which while imperfect, currently provide the best approach to this problem. We consider the limitations of functional imaging of the dopamine system in assessing the progression of Parkinson's Disease (PD) as well as the potential use of structural imaging and emerging progress in other biochemical and molecular markers. While there is no single biomarker that will satisfy all requirements, some combination is likely to be of great use in identifying those subjects most likely to benefit from neuroprotective therapies, as well as in monitoring the effects of these interventions.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
</country>
</list>
<tree><noCountry><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A Jon" last="Stoessl">A Jon Stoessl</name>
</noCountry>
<country name="Canada"><noRegion><name sortKey="Agarwal, Pankaj A" sort="Agarwal, Pankaj A" uniqKey="Agarwal P" first="Pankaj A" last="Agarwal">Pankaj A. Agarwal</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A86 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A86 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:22927101 |texte= Biomarkers for trials of neuroprotection in Parkinson's disease. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:22927101" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
This area was generated with Dilib version V0.6.23. |